Dr Aston currently serves as Non Executive Chairman of PharmAust. Roger brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. He has had extensive experience on boards and as Chief Executive Officer of many private and publically listed biotechnology companies. During his career, he has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors.
Dr Aston holds a B.Sc. (Hons) and Ph.D. degrees from the University of Manchester from 1975 to 1981.
Michael has over 25 years experience in technical, regulatory, commercial and management roles in research organisations and industry, including early stage, fast growing, private and publicly listed biotechnology companies.
In the Biotechnology industry, Michael has held leadership roles at MARP Therapeutics, Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During this time, he has guided a number of New Chemical Entities through discovery, preclinical and clinical development.
Michael has led a variety of US IND applications across a range of therapeutic areas and evaluated drugs and vaccines for registration during his engagement at the TGA. Michael currently sits on the Australian Boards of MARP Therapeutics, Impel Neuorpharma, Erasca and Inmagene.
Mr Bishop has 30 years’ experience in corporate finance and equity capital markets.
Having worked extensively in London and Sydney, first as a lawyer at Linklaters & Paines and Allen, Allen & Hemsley; and then as a stockbroker and investment banker at Ord Minnett, Robert Fleming and, since 1998, at his Sydney based corporate finance business, First Capital Markets.
He has extensive experience in the areas of stock market flotation’s, licensing and compliance work.
Mr Bassett is a Chartered Accountant specialising in corporate, financial and management advisory services. He has been involved with numerous public company listings and capital raisings. His involvement in the corporate arena has also taken in mergers and acquisitions and includes significant knowledge and exposure to the Australian financial markets. He has a wealth of experience in matters pertaining to the Corporations Act, ASX listing requirements, corporate taxation and finance. He is a director or company secretary of a number of public and private companies.
Neville is chairman of Westar Capital Limited, the holder of an Australian Financial Services Licence.
He is a Fellow of Chartered Accountants Australia and New Zealand. He was a Director/Councillor of a major not-for-profit organisation for 26 years, serving 8 years as Chairman before his retirement in 2017. Neville was awarded a Member of the Order of Australia (AM) in the 2015 Australia Day Honours.
Sam Wright has 20 years’ experience in the administration of ASX & LSE listed companies, corporate governance and corporate finance. He joined the Company as the Financial Controller in September 2006, was appointed as the Company Secretary in August 2007, and has been a Director of the Company since October 2008.
Mr Wright is Director and Company Secretary of a number of companies in Australia, North America and the United Kingdom. He is a member of the Australian Institute of Company Directors, the Financial Services Institute of Australasia, and the Governance Institute of Australia.
Mr Wright is the Managing Director of Perth-based corporate advisory firm Straight Lines Consultancy, specialising in the provision of corporate services to public companies.
Mr Wright has extensive experience in relation to public company responsibilities, including ASX, LSE and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, and shareholder relations with both retail and institutional investors.
Dr Duthy has over 19 years of direct financial market and executive level/Board experience with ASX-listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. This has included an IR/Corporate Development consultancy role with Nova Eye Medical (ASX:EYE), during which time a $100 million all-cash sale of its Lasers & Ultrasound business was completed with a subsequent $61 million on return made to shareholders. In addition, Dr Duthy was IR lead for Limeade Inc. (ASX:LME) which was acquired for $112 million in cash (325% premium) by WebMD Health Services (NASDAQ: WBMD) in August 2023.
Prior to this Dr Duthy was the former Head of Corporate Development and IR at Sirtex Medical (ASX:SRX), which was acquired for $1.9 billion in cash in September 2018 and remains the largest medical device acquisition in Australian corporate history. Dr Duthy is currently Non-Executive Chairman of Arovella Therapeutics (ASX:ALA), and an Executive Director of Neurotech International Ltd (ASX:NTI) and Invex Therapeutics (ASX:IXC).